173 related articles for article (PubMed ID: 15598439)
1. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
[TBL] [Abstract][Full Text] [Related]
3. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.
Hellmich B; Ciaglo A; Schatz H; Coakley G
Ann Rheum Dis; 2004 Jul; 63(7):862-6. PubMed ID: 15194585
[TBL] [Abstract][Full Text] [Related]
5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
[TBL] [Abstract][Full Text] [Related]
8. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
[TBL] [Abstract][Full Text] [Related]
9. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
[TBL] [Abstract][Full Text] [Related]
10. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542
[TBL] [Abstract][Full Text] [Related]
11. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].
Xu KF; Chen Y; Guo ZJ; Zhu YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782
[TBL] [Abstract][Full Text] [Related]
12. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor.
Dorr RT
Clin Ther; 1993; 15(1):19-29; discussion 18. PubMed ID: 8458048
[TBL] [Abstract][Full Text] [Related]
13. Development and application of a sensitive radioimmunoassay for human granulocyte-macrophage colony-stimulating factor able to measure normal concentrations in blood.
Mortensen BT; Schifter S; Pedersen LB; Jensen AN; Hovgaard D; Nissen NI
Exp Hematol; 1993 Sep; 21(10):1366-70. PubMed ID: 8359236
[TBL] [Abstract][Full Text] [Related]
14. A sensitive, rapid assay for the detection of human granulocyte-macrophage colony stimulating factor.
Conlon PJ; McMasters D; Prickett KS
J Biol Response Mod; 1987 Dec; 6(6):637-46. PubMed ID: 3330127
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
[TBL] [Abstract][Full Text] [Related]
16. Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).
Schwaab T; Tretter CP; Gibson JJ; Cole BF; Schned AR; Harris R; Fisher JL; Crosby N; Stempkowski LM; Heaney JA; Ernstoff MS
Prostate; 2006 May; 66(6):667-74. PubMed ID: 16425182
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
[TBL] [Abstract][Full Text] [Related]
18. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.
Hjelm Skog AL; Wadhwa M; Hassan M; Gharizadeh B; Bird C; Ragnhammar P; Thorpe R; Mellstedt H
Clin Cancer Res; 2001 May; 7(5):1163-70. PubMed ID: 11350880
[TBL] [Abstract][Full Text] [Related]
19. [Plasma granulocyte-macrophage colony stimulating factor (GM-CSF) and activity of enzymes in granulocytes of breast cancer patients].
Czygier M; Ławicki S; Szmitkowski M; Mroczko B
Przegl Lek; 2006; 63(8):654-7. PubMed ID: 17441377
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel.
Kageyama S; Kitano S; Hirayama M; Nagata Y; Imai H; Shiraishi T; Akiyoshi K; Scott AM; Murphy R; Hoffman EW; Old LJ; Katayama N; Shiku H
Cancer Sci; 2008 Mar; 99(3):601-7. PubMed ID: 18081877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
